Labentrol

Ciprofloxacin, the active ingredient in Labentrol, is a fluoroquinolone antibiotic presented as an injectable solution for intravenous administration. It is indicated for the treatment of severe bacterial infections, including urinary tract infections, respiratory tract infections, and skin and soft‑tissue infections, primarily in adult patients.

GNH USA supplies Labentrol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable cold‑chain logistics for injectable products. Customers benefit from consistent batch release and regulatory support across EU and global markets.

Labentrol (ciprofloxacin) is a fluoroquinolone antibiotic that targets bacterial DNA replication, making it suitable for several serious infections.

- Severe bacterial infections: achieves rapid bacterial eradication in systemic infections. - Urinary tract infections: clears pathogenic bacteria causing cystitis and pyelonephritis. - Respiratory tract infections: treats pneumonia and bronchitis caused by susceptible organisms. - Skin and soft‑tissue infections: resolves cellulitis, abscesses, and wound infections caused by Gram‑negative and Gram‑positive bacteria.

Ciprofloxacin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools, sometimes watery. - Headache: transient cranial discomfort. - Dizziness: occasional vertigo or light‑headedness. - Rash: mild skin erythema or pruritus. - Injection site pain: local discomfort at the IV site.

Serious or Rare Side Effects: - Tendon rupture: especially Achilles, may occur without warning. - QT interval prolongation: risk of cardiac arrhythmias. - Severe allergic reactions: anaphylaxis, angioedema. - Clostridioides difficile colitis: severe intestinal inflammation. - Hepatic toxicity: elevated liver enzymes or jaundice. - Seizures: particularly in patients with CNS disorders.

Ciprofloxacin requires careful assessment before use.

- Renal impairment: adjust dosing based on creatinine clearance. - History of tendon disorders: avoid use due to risk of tendon rupture. - Concomitant QT‑prolonging drugs: monitor cardiac rhythm. - Pregnancy and lactation: use only if benefits outweigh risks. - Known allergy to fluoroquinolones: contraindicated. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Ciprofloxacin can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: markedly reduce ciprofloxacin absorption. - Warfarin: may increase anticoagulant effect and bleeding risk.

Moderate Interactions (Monitor Closely): - Theophylline: increased plasma levels may cause toxicity. - NSAIDs: heightened risk of central nervous system adverse effects. - Corticosteroids: elevated chance of tendon injury. - Cyclosporine: may raise cyclosporine concentrations.